Clinical trials: Castrate-resistant Prostate Cancer
Prostate Cancer
Docetaxel and Diethylstilbestrol in the Treatment of Androgen Independent Prostate Cancer
This study is for men who have prostate cancer that has spread outside of the prostate gland and is no longer responding to hormone removal therapy.
- Trial name
- NCT00136526
- Testing
- Docetaxel and Diethylstilbestrol (DES)
- Volunteers
- 30 people
- Sponsor
- University of Washington
Adenocarcinoma of the Prostate, Bone Metastases
BMS-275291 in Treating Patients With Prostate Cancer That Has Not Responded to Hormone Therapy
BMS-275291 may stop the growth of prostate cancer by stopping blood flow to the tumor and by blocking the enzymes necessary for tumor cell growth.
- Conditions
- Adenocarcinoma of the Prostate, Bone Metastases, Hormone-resistant Prostate Cancer, Recurrent Prostate Cancer
- Trial name
- NCT00040755
- Testing
- rebimastat, laboratory biomarker analysis
- Where
- United States
- Volunteers
- 68 people
- Sponsor
- National Cancer Institute (NCI)
Castration-resistant Prostate Cancer
The Effects of Coenzyme A Combined With Abiraterone on Patients With CRPC
The purpose of this study is to compare the therapy effects and clinical safety of a regulatory metabolic compound, coenzyme A (CoA) with a marketed drug, abiraterone, in Chinese patients with castration-resistant prostate cancer…
- Trial name
- CoA-CRPC (NCT04839055)
- Testing
- Coenzyme A Combined With Abiraterone, Abiraterone
- Where
- China
- Volunteers
- 50 people
- Sponsor
- Jiangnan University
Metastatic Castration-resistant Prostate Cancer (CRPCa)
Impact of New Generation Hormono-therapy on Cognitive Functions in Elderly Patients Treated for a Metastatic Prostate Cancer
This study will assess the impact of the novel oral hormonal agents (abiraterone acetate or enzalutamide) among elderly metastatic prostate cancer patients.
- Trial name
- COG-PRO (NCT02907372)
- Testing
- neuropsychologic evaluation, oncogeriatric evaluation
- Where
- 6 sites in France
- Volunteers
- 163 people, healthy volunteers welcome
- Sponsor
- Centre Francois Baclesse
Metastatic Castration Resistant Prostate Cancer
A Study Evaluating Enzalutamide Pharmacokinetics and Pharmacodynamics, and Related Changes After Drug Switch
This is a study for evaluating enzalutamide pharmacokinetics and pharmacodynamics, and related changes after drug switch in Chinese patients with metastatic castration-resistant prostate cancer.
- Trial name
- NCT03778047
- Testing
- Enzalutamide, HC1119
- Where
- China
- Volunteers
- 10 people
- Sponsor
- Hinova Pharmaceuticals Inc.
Metastatic Castration Resistant Prostate Cancer
A Study to Assess the Benefit of Treatment Beyond Progression With Enzalutamide in Men Who Are Starting Treatment With Docetaxel After Worsening of Their Prostate Cancer When Taking Enzalutamide Alone
The purpose of the study was to understand if there was benefit in continued treatment with a medicine called enzalutamide, when starting treatment with docetaxel and prednisolone (a standard chemotherapy for prostate cancer)…
- Trial name
- PRESIDE (NCT02288247)
- Testing
- Enzalutamide, Docetaxel, Prednisolone
- Where
- 89 sites in Austria, Belgium and 14 more
- Volunteers
- 688 people
- Sponsor
- Astellas Pharma Europe Ltd.
Advanced or Metastatic ER+ HER2- Breast Cancer (mBC), Advanced or Metastatic Non-Small Cell Lung Cancer (NSCLC)
Phase 1 Study of OP-3136 in Advanced or Metastatic Solid Tumors
This is a first-in-human, open-label, multicenter phase 1 study to evaluate safety, tolerability, pharmacokinetics (PK), pharmacodynamics (PD), and preliminary efficacy of OP-3136, a lysine acetyltransferases 6A and 6B (KAT6A/B)…
- Conditions
- Advanced or Metastatic ER+ HER2- Breast Cancer (mBC), Advanced or Metastatic Non-Small Cell Lung Cancer (NSCLC), Advanced or Metastatic Castration-Resistant Prostate Cancer (mCRPC), Metastatic Breast Cancer
- Trial name
- NCT06784193
- Testing
- OP-3136, Fulvestrant, Palazestrant
- Where
- 25 sites in United States, Australia and 4 more
- Volunteers
- 180 people
- Sponsor
- Olema Pharmaceuticals, Inc.
Cancer, Castrate-Resistant Prostate Cancer
AMG 102 in Combination With Mitoxantrone and Prednisone in Subjects With Previously Treated Castrate Resistant Prostate Cancer
The primary objectives of this study are the following: Phase 1b: To identify a safe dose level of AMG 102, up to 15 mg/kg Q3W, to combine with mitoxantrone and prednisone (MP) Phase 2: To estimate with adequate precision the…
- Conditions
- Cancer, Castrate-Resistant Prostate Cancer, Mestastatic Prostate Cancer, Prostate Cancer
- Trial name
- NCT00770848
- Testing
- AMG 102, Mitoxantrone, Prednisone
- Volunteers
- 162 people
- Sponsor
- Amgen
Advanced/Metastatic Solid Tumor
KZR-261 in Subjects With Advanced Solid Malignancies
A first-in-human, open-label, multicenter, Phase 1 study of KZR-261 designed to assess the safety and tolerability, preliminary anti-tumor activity, and pharmacokinetics (PK) of KZR-261, as well as identify the recommended Phase…
- Trial name
- NCT05047536
- Testing
- KZR-261
- Where
- 12 sites in United States
- Volunteers
- 61 people
- Sponsor
- Kezar Life Sciences, Inc.
Prostate Cancer, Prostatic Neoplasms
Temsirolimus to Reverse Androgen Insensitivity for Castration-resistant Prostate Cancer
This study evaluates if temsirolimus causes a reduction in the serum levels of prostate-specific antigen (PSA) in male subjects with castration-resistant prostate cancer (CRPC).
- Conditions
- Prostate Cancer, Prostatic Neoplasms, Castrate-resistant Prostate Cancer (CRPC), Androgen-insensitive Prostate Cancer
- Trial name
- NCT01020305
- Testing
- Temsirolimus, Casodex (bicalutamide)
- Where
- United States
- Volunteers
- 5 people
- Sponsor
- Sandy Srinivas
Cancer of the Prostate, Metastatic Cancer
A Trial of 177Lu-PSMA617 Theranostic Versus Cabazitaxel in Progressive Metastatic Castration Resistant Prostate Cancer
This open label, randomised, stratified, 2-arm, multicentre, phase 2 trial aims to determine the activity and safety of Lu-PSMA vs cabazitaxel in men with progressive metastatic castration resistant prostate cancer
- Trial name
- TheraP (NCT03392428)
- Testing
- 177Lu-PSMA617, Cabazitaxel
- Where
- 11 sites in Australia
- Volunteers
- 201 people
- Sponsor
- Australian and New Zealand Urogenital and Prostate Cancer Trials Group
Castration-resistant Prostate Cancer
Study to Gather Information on the Safety and How Radium-223 Dichloride, an Alpha Particle-emitting Radioactive Agent, Works Under Routine Clinical Practice in Taiwan in Patients With Castration-resistant Prostate Cancer (CRPC) Which Has Spread to the Bone
In this observational study researchers want to gather more information about safety and survival in patients suffering from castration-resistant prostate cancer (CRPC) which has spread to the bone and were treated with…
- Trial name
- RAPIT (NCT04232761)
- Testing
- Radium-223 dichloride (Xofigo, BAY88-8223)
- Where
- Taiwan
- Volunteers
- 194 people
- Sponsor
- Bayer
Prostatic Neoplasms
Abemaciclib Plus Darolutamide in Prostate Cancer That Has Spread After Initial Treatment
The main purpose of this study is to learn more about the safety and tolerability of abemaciclib when given in combination with darolutamide to participants with prostate cancer that has spread after initial treatment.
- Trial name
- NCT05999968
- Testing
- Abemaciclib, Darolutamide, LHRH agonist/antagonist
- Where
- 13 sites in United States, Germany and 1 more
- Volunteers
- 10 people
- Sponsor
- Eli Lilly and Company
Metastatic Castration-Resistant Prostate Cancer
ZEN003694 and Enzalutamide Versus Enzalutamide Monotherapy in Metastatic Castration-Resistant Prostate Cancer
This is an open-label, randomized, Phase 2b study of ZEN003694 in combination with enzalutamide vs. enzalutamide monotherapy in patients with mCRPC who have progressed on prior abiraterone by PCWG3 criteria.
- Trial name
- NCT04986423
- Testing
- ZEN003694, Enzalutamide
- Where
- 31 sites in United States, China
- Volunteers
- 200 people
- Sponsor
- Zenith Epigenetics
Metastatic Castration Resistant Prostate Cancer (CRPC)
Phase IIB Clinical Trial of Hamsa-1™ in Metastatic Castration Resistant Prostate Cancer (CRPC)
Hamsa-1™ is an anti-angiogenic drug combination designed for the treatment of cancer. The investigational product Hamsa-1™ comprises of four well-known active components.
- Trial name
- TLH-202 (NCT00684970)
- Testing
- Hamsa-1™ TL-118
- Where
- 5 sites in Israel
- Volunteers
- 100 people
- Sponsor
- Tiltan Pharma Ltd.
Prostate Cancer, Castrate Resistant Prostate Cancer
Clinical Outcomes of Use of Olaparib in Castration Resistant Prostate Cancer
This is an observational, retrospective/prospective, multicenter study designed to define, overall survival, clinical outcomes and predictive/prognostic factors of a consecutive population of mCRPC patients treated with olaparib…
- Conditions
- Prostate Cancer, Castrate Resistant Prostate Cancer, BRCA Mutation
- Trial name
- COROS (NCT06783127)
- Testing
- Olaparib
- Where
- 2 sites in Italy
- Volunteers
- 3,000 people
- Sponsor
- Santa Chiara Hospital
Prostate Cancer, Metastatic Prostate Cancer
LuCarbo - a Study of 177Lu-PSMA-617 Plus Carboplatin in Metastatic Castrate-resistant Prostate Cancer
The purpose of this study is to see whether the combination of a chemotherapy drug, carboplatin, along with the radioligand treatment, 177Lu-PSMA-617, is safe in treating prostate cancer and whether the combination is effective…
- Conditions
- Prostate Cancer, Metastatic Prostate Cancer, Metastatic Castration-resistant Prostate Cancer
- Trial name
- NCT06303713
- Testing
- Carboplatin, 177Lu-PSMA-617
- Where
- 3 sites in United States
- Volunteers
- 37 people
- Sponsor
- Dana-Farber Cancer Institute
Prostate Cancer Metastatic
Early Access to Cabazitaxel in Patients With Metastatic Hormone Refractory Prostate Cancer Previously Treated With a Docetaxel-containing Regimen
The purpose of this study is to allow patients similar to that evaluated in the TROPIC trial (NCT00417079), and Investigators access to cabazitaxel for the management of metastatic Hormone Refractory Prostate Cancer (mHRPC) in…
- Trial name
- NCT01254279
- Testing
- CABAZITAXEL
- Where
- 165 sites in Australia, Austria and 27 more
- Volunteers
- 984 people
- Sponsor
- Sanofi
Metastatic Castration Resistant Prostate Cancer
Targeted Alpha Therapy With 225Actinium-Prostate Specific Membrane Antigen (PSMA)-I&T of Castration-resISTant Prostate Cancer (TATCIST).
The treatment regimen will consist of 4 doses of FPI-2265
- Trial name
- TATCIST (NCT05219500)
- Testing
- FPI-2265
- Where
- 2 sites in United States
- Volunteers
- 115 people
- Sponsor
- Fusion Pharmaceuticals Inc.
Advanced Prostate Cancer
Study of HRS-5041 in Patients With Metastatic Castration Resistant Prostate Cancer (mCRPC)
The purpose of this study is to assess the safety, tolerability and preliminary efficacy of HRS-5041 in men with progressive metastatic castration resistant prostate cancer.
- Trial name
- NCT05942001
- Testing
- HRS-5041, Docetaxel injection, Abiraterone acetate tablets
- Where
- China
- Volunteers
- 100 people
- Sponsor
- Jiangsu HengRui Medicine Co., Ltd.
The first 1,020 results can be paged through. Add a filter or change the sort order to reach the rest.